V
Vericel Corporation (VCEL)
NGM – Real vaqt narxi. Valyuta: USD
46.23
+3.33 (7.76%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
46.16
-0.07 (-0.15%)
Bozordan keyin: Jun 26, 2026, 6:27 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
46.23
+3.33 (7.76%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
46.16
-0.07 (-0.15%)
Bozordan keyin: Jun 26, 2026, 6:27 PM EDT
Vericel Corporation, tijorat bosqichidagi biofarmatsevtika kompaniyasi, Shimoliy Amerikadagi sport tibbiyoti va og'ir kuyishlarni davolash bozorlari uchun hujayrali terapiya va maxsus biologik mahsulotlarni tadqiq qilish, ishlab chiqish, ishlab chiqarish va tarqatish bilan shug'ullanadi. Kompaniya sport tibbiyoti uchun MACI, simptomatik va tizzaning bir yoki bir nechta to'liq qalinlikdagi tog'ay nuqsonlarini tiklash uchun cho'chqa kollagen membranasi ustida avtolog kultivatsiya qilingan xondrotsitlarni o'z ichiga olgan avtolog hujayrali terapiya mahsulotlarini, og'ir kuyishlar uchun Epicel, kattalar va bolalarda chuqur-dermal yoki to'liq qalinlikdagi kuyishlarni davolash uchun doimiy teri almashtirish gumanitar vositasini va NexoBrid, chuqur qisman qalinlikdagi va/yoki to'liq qalinlikdagi termal kuyishlari bo'lgan kattalar va bolalarda nekrozni olib tashlash uchun biologik etim mahsulotini sotadi. Vericel Corporation ilgari Aastrom Biosciences, Inc. nomi bilan tanilgan va 2014-yil noyabr oyida Vericel Corporation deb o'zgartirilgan. Kompaniya 1989-yilda ro'yxatga olingan va shtab-kvartirasi Burlington, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. | Chief Medical Officer |
| Mr. Dominick C. Colangelo Esq. | CEO, President & Director |
| Mr. Eric Burns | Vice President of Finance & Investor Relations |
| Mr. Jonathan D. Siegal | Principal Accounting Officer, VP & Corporate Controller |
| Mr. Joseph Anthony Mara Jr. | CFO & Treasurer |
| Mr. Michael Halpin | Chief Operating Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-18 | 8-K | ef20073865_8k.htm |
| 2026-05-07 | 8-K | vcel-20260507.htm |
| 2026-05-07 | 10-Q | vcel-20260331.htm |
| 2026-05-01 | 8-K | ef20071924_8k.htm |
| 2026-03-19 | DEFA14A | lvcel2026_defa14a.htm |
| 2026-03-19 | DEF 14A | vcel_courtesy-pdf.pdf |
| 2026-02-26 | 8-K | vcel-20260226.htm |
| 2026-02-26 | 10-K | vcel-20251231.htm |
| 2026-01-13 | 8-K | ef20062769_8k.htm |
| 2025-11-06 | 8-K | vcel-20251106.htm |
| Mr. Mike Gilligan | Senior Vice President of Sales |
| Mr. Patrick J. Fowler | Senior Vice President of Corporate Development & Strategy |
| Mr. Roland DeAngelis | Chief Marketing Officer |
| Mr. Sean C. Flynn | Chief Legal Officer |